Table 1.
Patient, tumor, and treatment characteristics.
| Characteristic | Percent of assessable patients: all cohorts (absolute number) | Percent of assessable patients: MSKCC + CCF only (absolute number) | Percent of assessable patients: French only (absolute number) |
|---|---|---|---|
|
| |||
| Site | |||
| MSKCC | 34 (241) | 55 (241) | 0.0 (0) |
| CCF | 28 (196) | 45 (196) | 0.0 (0) |
| French | 38 (265) | 0.0 (0) | 100.0 (265) |
|
| |||
| Gender | |||
| Men | 58 (404) | 60 (246) | 56 (158) |
| Women | 42 (298) | 40 (191) | 44 (107) |
|
| |||
| Age (yrs) | |||
| ≤73.5 | 38 (265) | 36 (157) | 41 (108) |
| 73.6–75.5 | 17 (122) | 16 (72) | 19 (50) |
| 75.6–76.5 | 10 (68) | 10 (44) | 9 (24) |
| 76.6–78.5 | 13 (89) | 11 (50) | 15 (39) |
| 78.6–83.5 | 18 (130) | 21 (90) | 15 (40) |
| ≥83.6 | 4 (28) | 6 (24) | 1 (4) |
|
| |||
| KPS | |||
| <70 | 31 (175) | 33(135) | 27 (40) |
| 70–100 | 69 (387) | 67 (279) | 73 (108) |
|
| |||
| Symptoms | |||
| Headache | 18 (125) | 19 (80) | 17 (45) |
| Seizure | 19 (130) | 17 (73) | 22 (57) |
| Hemiparesis | 17 (117) | 26 (112) | 2 (5) |
| Language | 18 (123) | 27 (117) | 2 (6) |
| Mental status | 47 (326) | 46 (199) | 48 (127) |
| Visual | 7 (51) | 11 (45) | 2 (6) |
| General sensory | 3 (23) | 5 (23) | 0 (0) |
| Cranial nerves | 3 (19) | 4 (17) | <1 (2) |
| Increased ICP | 3 (24) | 1 (5) | 7 (19) |
| Gait | 12 (82) | 18 (79) | 1 (3) |
|
| |||
| Lesion number | |||
| Single | 88 (381) | 88 (381) | Not recorded |
| Multiple | 12 (54) | 12 (54) | Not recorded |
|
| |||
| Lesion location | |||
| Frontal | 38 (165) | 38 (165) | Not detailed* |
| Temporal | 38 (166) | 38 (166) | |
| Parietal | 36 (154) | 36 (154) | |
| Occipital | 11 (48) | 11 (48) | |
| Corpus callosum | 6 (24) | 6 (24) | |
| Cerebellum | <1 (1) | <1 (1) | |
| Brainstem | <1 (2) | <1 (2) | |
| Gliomatosis | <1 (2) | <1 (2) | |
| Other | 5 (22) | 5 (22) | |
|
| |||
| Surgery | |||
| Biopsy | 47 (324) | 36 (154) | 64 (170) |
| PR | 33 (231) | 43 (186) | 17 (45) |
| GTR | 20 (141) | 21 (91) | 19 (50) |
|
| |||
| RT | |||
| Yes | 78 (419) | 72 (304) | 45 (119) |
| No | 22 (118) | 28 (118) | 55 (146) |
|
| |||
| RT dose (cGy) | |||
| <6000 | 54 (202) | 60 (156) | 40 (48) |
| ≥6000 | 46 (172) | 40 (104) | 60 (71) |
|
| |||
| Chemotherapy | |||
| Yes | 35 (234) | 35 (143) | 34 (91) |
| No | 65 (442) | 65 (268) | 66 (174) |
MSKCC=Memorial Sloan-Kettering Cancer Center; CCF=Cleveland Clinic Foundation; KPS=Karnofsky performance status; PR=partial resection; GTR=gross total resection; RT=radiation therapy. .
*
Tumor location were noted but rarely detailed in the French study. Globally, 144 patients (54%) presented with neurologic deficits in the French cohort.